US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Cyclooxygenase inhibitor
pharma · Non-Alcoholic Fatty Liver Disease · Non-alcoholic Steatohepatitis (NASH) Cirrhosis · MDGL
Madrigal Pharmaceuticals EU
Madrigal Pharmaceuticals EU Limited
Madrigal Pharmaceuticals EU drug portfolio — 11 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
200 Barr-Harbor Dr, Suite 200, Conshohocken, Pennsylvania 19428, US HQ
2016 Founded
1,071 Employees
Public company Type
MDGL · NYSE Ticker
Company details
- Status
- Public
- HQ
- 200 Barr-Harbor Dr, Suite 200, Conshohocken, Pennsylvania 19428, US
- Founded
- 2016
- Employees
- 1,071
- Programs
- 16
- Drugs
- 11
- Patents
- 26
Madrigal Pharmaceuticals EU pipeline
Portfolio lens on 11 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Madrigal Pharmaceuticals EU drug portfolio — 11 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved.
-
US regulatory status: approved. Molecular target: Voltage-gated L-type calcium channel.
- Target
- Voltage-gated L-type calcium channel
- Mechanism
- Voltage-gated L-type calcium channel blocker
-
Development asset linked to Madrigal Pharmaceuticals EU in public FDA and regional records. Mechanism: HMG-CoA reductase inhibitor.
- Mechanism
- HMG-CoA reductase inhibitor
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
Development asset linked to Madrigal Pharmaceuticals EU in public FDA and regional records.
-
Development asset linked to Madrigal Pharmaceuticals EU in public FDA and regional records.
-
resmetirom
Alimentary tract and metabolism (A05)US regulatory status: approved. Molecular target: Thyroid hormone receptor beta.
- Target
- Thyroid hormone receptor beta
- Mechanism
- Thyroid hormone receptor beta-1 agonist
-
US regulatory status: approved. Molecular target: 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
- Target
- 3-hydroxy-3-methylglutaryl-coenzyme A reductase
- Mechanism
- HMG-CoA reductase inhibitor
-
Development asset linked to Madrigal Pharmaceuticals EU in public FDA and regional records.
-
Development asset linked to Madrigal Pharmaceuticals EU in public FDA and regional records.